Paper Details

  1. Home
  2. Paper Details

Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.

Author: Bani-SadrFirouze, DunnDavid, GilsonRichard, JainMamta K, KuzushitaNoriyoshi, MaussStefan, NúñezMarina, NüeschReto, PetersMarion, PillayDeenan, PriceHuw, ReibergerThomas, StephanChristoph, TanLionel, de Vries-SluijsTheodora

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Hepatitis B is common in people with HIV, and has become a more significant concern as treatments for HIV have improved. Tenofovir (TDF) is a powerful medication for hepatitis B, with a low risk of resistance. However, there are still questions about TDF's use, including how many people successfully reduce their viral levels, how long the effect lasts, and whether it's less effective for people who have previously used other hepatitis B medications.
Paper Details　
Original Abstract of the Article :
Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707972/

データ提供：米国国立医学図書館（NLM）

Tenofovir for HBV Suppression in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis

The [hepatitis B virus (HBV)] infection is a significant public health concern, particularly in individuals coinfected with [human immunodeficiency virus (HIV)]. This systematic review and meta-analysis assessed the efficacy of [tenofovir (TDF)] in suppressing HBV viral load in HBV/HIV coinfected patients. The authors reviewed the available literature to determine the proportion of patients achieving HBV suppression, the duration of suppression, and the impact of prior HBV treatment on TDF efficacy. Their findings suggest that TDF is a highly effective antiviral agent for HBV suppression, offering a promising treatment option for coinfected patients.

Tenofovir: A Powerful Weapon Against HBV in Coinfected Patients

The study's findings highlight the effectiveness of TDF in suppressing HBV viral load in HBV/HIV coinfected patients. The authors' analysis demonstrates that TDF offers a high rate of HBV suppression, with a significant proportion of patients achieving sustained viral load reduction. This research provides valuable insights into the use of TDF as a cornerstone treatment for HBV/HIV coinfection, offering hope for improved patient outcomes.

Navigating the Complexities of HBV/HIV Coinfection: A New Era of Treatment Options

This research underscores the importance of effective treatment options for HBV/HIV coinfection. The authors' comprehensive review and meta-analysis provide strong evidence for the effectiveness of TDF in suppressing HBV viral load, highlighting its potential as a key component of treatment regimens for coinfected patients. This study contributes to the growing body of knowledge regarding the management of this complex condition and offers hope for improved patient outcomes.

Dr.Camel's Conclusion

The management of HBV/HIV coinfection is a challenging journey through a desert of complex medical considerations. This research sheds light on the effectiveness of TDF as a powerful weapon against HBV in coinfected patients, offering a beacon of hope in the fight against this dual threat. I am encouraged by the findings and believe that further research will continue to refine treatment strategies, leading to improved health outcomes for patients facing this complex condition.

Date :
  1. Date Completed 2014-03-31
  2. Date Revised 2023-11-15
Further Info :

Pubmed ID

23874527

DOI: Digital Object Identifier

PMC3707972

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.